ABBV-CLS-628

DRUG2 trials

Sponsors

AbbVie Deutschland GmbH & Co. KG, Calico Life Sciences LLC

Conditions

Autosomal Dominant Polycystic Kidney Disease

Phase 2

ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

RecruitingNCT06902558

Calico Life Sciences LLCAutosomal Dominant Polycystic Kidney Disease

Start: 2025-06-09End: 2029-08-01Target: 240Updated: 2026-09-01

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

RecruitingCTIS2024-517143-31-00

AbbVie Deutschland GmbH & Co. KGAutosomal Dominant Polycystic Kidney Disease

Start: 2025-07-18Target: 98Updated: 2025-09-12